Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial The MMR-161 Study Group
The MMR-161 Study Group; Ahonen, Anitta; Berry, Andrea (2018)
The MMR-161 Study Group
Ahonen, Anitta
Berry, Andrea
et al.2018
Vaccine 36 38
5781-5788
Lääketieteen ja biotieteiden tiedekunta - Faculty of Medicine and Life Sciences